Sophia Humphreys, PharmD, explains that expanding biosimilars into new therapeutic areas faces hesitance due to maintenance therapies, emphasizing the importance of education, and highlights factors ...

Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the ...

Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA Study ...

Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA Study ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies ...

The European Union's (EU) approach to biosimilars has revolutionized the biopharmaceutical market by driving innovation, ...

Transformative cell and gene therapies (CGT) offer promising treatments for serious conditions, but high costs and complex ...

Ivo Abraham, PhD, RN, director of the Center for Health Outcomes and PharmacoEconomic Research at the University of Arizona ...

Number 5: The FDA has approved Imuldosa (ustekinumab-srlf), a biosimilar referencing Stelara (ustekinumab), for the treatment of autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...

The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar ...